Montgomery A M, Wing M G, Lachmann P J
Molecular Immunopathology Unit, MRC Centre, Cambridge, U.K.
Immunology. 1992 Feb;75(2):217-23.
This paper describes a T-cell targeting strategy based on the use of an antigen-monoclonal antibody heteroconjugate. A rat anti-idiotypic monoclonal antibody specific for a murine B-cell lymphoma was conjugated to the purified protein derivative (PPD) of tuberculin. This construct selectively delivered up to 4.5 x 10(4) molecules of PPD onto each tumour cell. Targeted PPD was internalized for endosomal processing and was presented in association with the I-A class II restriction element to PPD-reactive T-helper (Th) cells. Activated Th cells were demonstrated to proliferate and secrete significant levels of tumour necrosis factor (TNF). Such lymphokine secretion was observed at a PPD concentration as low as 1 ng/ml. Despite the secretion of TNF, the B-cell lymphoma was found to be resistant to autonomous Th-mediated cytotoxicity. Targeted Th cells did, however, activate tumourcidal macrophages that subsequently mediated significant tumour cytostasis. Based on this observation, it is proposed that the targeting system described may be exploited as the basis for a future immunotherapeutic strategy.
本文描述了一种基于抗原 - 单克隆抗体异源缀合物的T细胞靶向策略。将一种针对鼠B细胞淋巴瘤的大鼠抗独特型单克隆抗体与结核菌素的纯化蛋白衍生物(PPD)偶联。这种构建体可在每个肿瘤细胞上选择性递送多达4.5×10⁴个PPD分子。靶向的PPD被内化用于内体加工,并与II类I - A限制性元件一起呈递给PPD反应性T辅助(Th)细胞。已证明活化的Th细胞会增殖并分泌大量肿瘤坏死因子(TNF)。在低至1 ng/ml的PPD浓度下即可观察到这种淋巴因子分泌。尽管分泌了TNF,但发现B细胞淋巴瘤对自主Th介导的细胞毒性具有抗性。然而,靶向的Th细胞确实激活了具有杀肿瘤作用的巨噬细胞,随后巨噬细胞介导了显著的肿瘤细胞生长停滞。基于这一观察结果,有人提出所描述的靶向系统可作为未来免疫治疗策略的基础加以利用。